Answer:
Omega-3 fatty acids can help lower triglycerides, a type of fat that clogs arteries. Monounsaturatedfatsincludecanola,olive, and peanut oils. Other good sources are olives, avocados, nuts, and nut butters. These fats can help lower "bad" (LDL) cholesterol and raise "good" (HDL) cholesterol.
Explanation:
My dad takes omegas because he has high cholestrail which that also helps with heart problems.
Answer:
I would use a specialized or preformed matrix for the posterior sector.
Explanation:
Losing a cusp is a much more critical situation, that is, there will be less tooth remnant and less resistance to functional and parafunctional forces.
The matrices that are usually used in the posterior sector are matrices that must be burnished and already come with a format to better restore the functional unit of the occlusal surface.
It is important to clarify that cusps are only in the posterior sector and not in the anterior sector.
The cusps, even if they have the most correct selection of the matrix, will fail in their restoration if they are not performed according to the patient's occlusion, under a good dental integration system such as adhesion through resins, and respecting the normal antomy of the piece to be restored.
Answer:
polar bonds
Explanation:
i had the same question on a test of mine and i got it right
Answer:
The mantle is solid.
Explanation:
The mantle is the mostly-solid bulk of Earth's interior. The mantle lies between Earth's dense, super-heated core and its thin outer layer, the crust. The mantle is about 2,900 kilometers thick, and makes up 84% of Earth's total volume.
Answer:
Phase III
Explanation:
The given condition fall in the trial phase (Phase III) of cinical study which aims to:
- Determine drug's effectiveness (primary goal)
- Determine long-term drug safety
- Confirm findings
In Phase III, randomised, double-blind, placebo-controlled, parallel group study is majorly to evaluate the efficacy and safety of placebo in episodic migraine prevention in children (6 to < 12 years of age) and adolescents (12 to < 18 years of age).
The trial consists of four phases: screening; double-blind therapy period for 24 weeks in which placebo or Erenumab is given to subject as dose 1, dose 2 or dose 3 (based on the participant's body weight) once a month via subcutaneous injection; optional dose level blinded extension phase (40 weeks) which involves subjects recieve dose1, 2 and 3 of placebo, and at last it follows a safety follow-up phase for 12 weeks (after 16 weeks of the last dose of investigational drug).
Hence, the clinical phase is phase III.
